NCT05332366

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled, Single Site, Exploratory Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial also investigated the clinical effect of delgocitinib cream on FFA compared to a placebo cream.

Conditions

• Frontal Fibrosing Alopecia

Interventions

Type	Name	Description
DRUG	Delgocitinib cream	Cream for topical application
DRUG	Delgocitinib cream vehicle	The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

Timeline

• Start date: 2022-04-19
• Primary completion: 2023-02-13
• Completion: 2023-05-22
• First posted: 2022-04-18
• Last updated: 2025-03-06
• Results posted: 2025-02-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study